These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 28124979)

  • 1. Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases.
    Lee JU; Shin W; Son JY; Yoo KY; Heo YS
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28124979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action.
    Bourne T; Fossati G; Nesbitt A
    BioDrugs; 2008; 22(5):331-7. PubMed ID: 18778114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.
    Nesbitt A; Fossati G; Bergin M; Stephens P; Stephens S; Foulkes R; Brown D; Robinson M; Bourne T
    Inflamm Bowel Dis; 2007 Nov; 13(11):1323-32. PubMed ID: 17636564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis.
    Lim H; Lee SH; Lee HT; Lee JU; Son JY; Shin W; Heo YS
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29518978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for treating tumor necrosis factor α (TNFα)-associated diseases with the therapeutic antibody infliximab.
    Liang S; Dai J; Hou S; Su L; Zhang D; Guo H; Hu S; Wang H; Rao Z; Guo Y; Lou Z
    J Biol Chem; 2013 May; 288(19):13799-807. PubMed ID: 23504311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α.
    Ueda N; Tsukamoto H; Mitoma H; Ayano M; Tanaka A; Ohta S; Inoue Y; Arinobu Y; Niiro H; Akashi K; Horiuchi T
    Inflamm Bowel Dis; 2013 May; 19(6):1224-31. PubMed ID: 23619715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis.
    Palframan R; Airey M; Moore A; Vugler A; Nesbitt A
    J Immunol Methods; 2009 Aug; 348(1-2):36-41. PubMed ID: 19567252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development and Optimization of Therapeutic Analogues of Anti-TNFα Antibody Infliximab].
    Yu XJ; Shen YF; Dong J; Li T; Wang C; Zhang YJ; Wang LF; Meng YC; Yang Y; Wang HJ; Lei CH; Hu S; Li BH
    Mol Biol (Mosk); 2018; 52(4):628-633. PubMed ID: 30113028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor-alpha antagonists: differential clinical effects by different biotechnological molecules.
    Licastro F; Chiappelli M; Ianni M; Porcellini E
    Int J Immunopathol Pharmacol; 2009; 22(3):567-72. PubMed ID: 19822073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol.
    Pasut G
    BioDrugs; 2014 Apr; 28 Suppl 1():S15-23. PubMed ID: 24687235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases.
    Deeks ED
    BioDrugs; 2016 Dec; 30(6):607-617. PubMed ID: 27704400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region.
    van Schie KA; Hart MH; de Groot ER; Kruithof S; Aarden LA; Wolbink GJ; Rispens T
    Ann Rheum Dis; 2015 Jan; 74(1):311-4. PubMed ID: 25342759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
    Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor α-associated diseases from a molecular view.
    Hu S; Liang S; Guo H; Zhang D; Li H; Wang X; Yang W; Qian W; Hou S; Wang H; Guo Y; Lou Z
    J Biol Chem; 2013 Sep; 288(38):27059-27067. PubMed ID: 23943614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer.
    Porter C; Armstrong-Fisher S; Kopotsha T; Smith B; Baker T; Kevorkian L; Nesbitt A
    J Reprod Immunol; 2016 Aug; 116():7-12. PubMed ID: 27123565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Tumor Necrosis Factor α Therapeutics Differentially Affect
    Arens K; Filippis C; Kleinfelder H; Goetzee A; Reichmann G; Crauwels P; Waibler Z; Bagola K; van Zandbergen G
    Front Immunol; 2018; 9():1772. PubMed ID: 30108591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of endothelial cell activity by inhibition of TNFα.
    Shu Q; Amin MA; Ruth JH; Campbell PL; Koch AE
    Arthritis Res Ther; 2012 Apr; 14(2):R88. PubMed ID: 22534470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitors.
    Tragiannidis A; Kyriakidis I; Zündorf I; Groll AH
    Mycoses; 2017 Apr; 60(4):222-229. PubMed ID: 27766695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour necrosis factor α antagonists in the treatment of rheumatoid arthritis: an immunological perspective.
    Meroni PL; Valesini G
    BioDrugs; 2014 Apr; 28 Suppl 1():S5-13. PubMed ID: 24687234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recombinant proteins or monoclonal antibodies: comparative properties and interest in rheumatoid arthritis].
    Sibilia J
    Med Sci (Paris); 2009 Dec; 25(12):1033-8. PubMed ID: 20035675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.